Trials soon ready
Clinical trials expected to report results within the next 6 months, ranked by potential. Each trial shows its estimated finish date — explained in plain language.
Showing the top 50 of 20670 trials in this window.
-
Can a bone marrow trick make face transplants safer?
⭐️ CURE ⭐️ Recruiting nowBackground: The human face is critically important for breathing, eating, seeing, and speaking/ communicating, but its most important job may be to look like a human face. Devastating facial deformities often cause affected individuals to avoid human contact and disappear from so…
Results expected Aug 2026 (estimated)
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Can a One-Two punch of CAR-T and lenalidomide beat tough leukemia?
⭐️ CURE ⭐️ Recruiting nowThis is a Phase I/II interventional, open-label treatment study designed to evaluate the safety and efficacy of concomitant therapy with anti-CD19 CAR T-cells and Lenalidomide in adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who have been pretreated w…
Results expected Aug 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Vitebsk Regional Clinical Cancer Centre • Aim: ⭐️ CURE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Gene therapy breakthrough offers hope for rare brain disease
Disease control ENROLLING_BY_INVITATIONCanavan Disease is a congenital white matter disorder caused by mutations to the gene encoding for aspartoacylase (ASPA). Expression of ASPA is restricted to oligodendrocytes, the sole white matter producing lineage in the brain. ASPA supports myelination in the capacity of its s…
Results expected Aug 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Myrtelle Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
One-Time gene therapy aims to restore muscle in boys with duchenne
Disease control OngoingRGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, …
Results expected Sep 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
RegenxBio Inc. · RGNX NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
One shot, six months of malaria shield? a new trial tests a powerful antibody in children
Prevention OngoingBackground and rationale: Hospitalised children with severe anaemia remain at high risk of dying or requiring hospital readmission for at least 6 months after discharge. In highly malaria-endemic settings, malaria is a major contributor to these post-discharge readmissions and de…
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: Liverpool School of Tropical Medicine • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
New hope for kids with blood cancer: tailored treatments aim to boost cure rates and cut side effects
Disease control OngoingThe overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific genomic features and targeted treatment approaches to improve the cure rate and quality of life of children with acute lymphoblastic leukemia (A…
Results expected Sep 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
⭐️ CURE ⭐️ OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: Arcellx, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Reward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company ModerateA small company — one failure carries real weight.
-
Could a Virus-Like particle vaccine outsmart polio?
⭐️ VACCINE ⭐️ OngoingThis is a phase I/II randomized, double-blind, and positive-controlled study. Participants in the phase I toddler group will receive 1 dose of either high dose VLP-Polio (Dose H) or control vaccine in a ratio of 3:1. The phase I infant cohort will have 4 arms randomly assigned to…
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 08, 2026 00:03 UTC
CanSino Biologics Inc. · 6185 HKEXReward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Could a stem cell transplant cure immune diseases?
⭐️ CURE ⭐️ Recruiting nowBackground: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective:…
Results expected Oct 2026 (estimated)
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 12:28 UTC
-
Can specially trained immune cells flush out hidden HIV?
⭐️ CURE ⭐️ OngoingThis is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following…
Results expected Nov 2026 (estimated)
Phase: PHASE1 • Sponsor: Catherine Bollard • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
Could one drug replace the standard triple therapy for rectal cancer?
Disease control OngoingThe purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical respon…
Results expected Nov 2026 (estimated)
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works HighAn incremental result rather than a breakthrough.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New hope for advanced breast cancer: targeted drug combo tested in major trial
Disease control OngoingThe study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New hope for kids with leukemia: smarter chemo dosing could boost cures
⭐️ CURE ⭐️ OngoingAcute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous ly…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Dana-Farber Cancer Institute • Aim: ⭐️ CURE ⭐️
Last updated Jul 18, 2026 00:00 UTC
-
One-Time gene shot aims to stop bleeding in hemophilia a
Disease control Recruiting nowThis study is a single-arm, open-label, multicenter study evaluating the efficacy and safety of GS1191-0445 injection as a single dose in Chinese subjects with hemophilia A. GS1191-0445 is an AAV8-based gene therapy vector designed to express B-domain deleted human factor VIII (…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Gritgen Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Engineered immune cells take aim at Hard-to-Treat lung cancer
⭐️ CURE ⭐️ Recruiting nowA study to evaluate the safety and feasibility of α-PD-L1/4-1BB DLL3 Chimeric Antigen Receptor (CAR)-T (BHP01) in patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC) and determine the appropriate CAR-T cell dose. Next, In dose expansion phase, patients were assign two…
Results expected Dec 2026 (estimated)
Phase: PHASE1 • Sponsor: Sichuan University • Aim: ⭐️ CURE ⭐️
Last updated Jul 23, 2026 00:00 UTC
-
Hepatitis b cure breakthrough? new combo aims for 50%+ cure rate
⭐️ CURE ⭐️ Recruiting nowExploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overa…
Results expected Dec 2026 (estimated)
Phase: PHASE4 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: ⭐️ CURE ⭐️
Last updated Jul 09, 2026 00:00 UTC
-
One-Time gene fix could rescue 'Bubble Boy' disease
Disease control Recruiting nowThis is a Phase I/II trial of in vivo lentiviral gene therapy for treating adenosine deaminase severe combined immunodeficiency (ADA-SCID) using a self-inactivating lentiviral vector (LV) ivlv-ADA to functionally correct the genetic defect. The primary objectives are to evaluate …
Results expected Dec 2026 (estimated)
Phase: NA • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Bubble boy disease gene therapy trial launches
Disease control Recruiting nowThis is a Phase I/II gene therapy trial treating X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector (ivlv-X1) to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the direct intr…
Results expected Dec 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Major RSV vaccine trial for seniors nears completion
⭐️ VACCINE ⭐️ OngoingEfficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * Th…
Results expected Jan 2027 (estimated)
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Thinking your way to movement: brain-computer interface tested for hand function in tetraplegia
Disease control Recruiting nowThis prospective, multicenter, single-arm clinical trial will enroll subjects with tetraplegia secondary to spinal cord injury. An implantable brain-computer interface system for compensatory hand motor function will be used to reconstruct upper-limb function, so as to evaluate t…
Results expected Jan 2027 (estimated)
Phase: NA • Sponsor: NeuroXess Technology (shanghai) Co.,Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can donor immune cells be engineered to fight blood cancer?
⭐️ CURE ⭐️ Recruiting nowKCAT19 is a single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age 16-65 years) with high risk, relapsed/refractory (r/r) B cell malignancies.
Results expected Feb 2027 (estimated)
Phase: PHASE1 • Sponsor: University College, London • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Can adding radiation boost immunotherapy against spread head and neck cancer?
Disease control Recruiting nowStudy to evaluate the efficacy of treatment by radiotherapy and pembrolizumab in newly diagnosed metastatic head \& neck cancers
Results expected Oct 2026 (estimated)
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Womb transplants could let infertile women give birth
Disease control OngoingThis study aims to investigate the treatment of absolute uterine infertility (AUI) due to congenital or surgical absence of a uterus or presence of a nonfunctioning uterus. The investigators will follow a model based on a Swedish study to enroll 20 women with functioning ovaries …
Results expected Nov 2026 (estimated)
Phase: NA • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease
⭐️ CURE ⭐️ Recruiting nowThis is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical or MUD allogeneic stem cell transplantation with CD…
Results expected Dec 2026 (estimated)
Phase: PHASE2 • Sponsor: New York Medical College • Aim: ⭐️ CURE ⭐️
Last updated Jul 29, 2026 00:00 UTC
-
Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
⭐️ CURE ⭐️ Recruiting nowEnrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFO…
Results expected Dec 2026 (estimated)
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: ⭐️ CURE ⭐️
Last updated Jul 31, 2026 00:00 UTC
-
New TB vaccine aims to prevent active lung disease in adults
⭐️ VACCINE ⭐️ OngoingThis study is a multicenter, double-blind, randomized, placebo-controlled Phase III trial designed to evaluate the efficacy and safety of the GamTBvac recombinant subunit tuberculosis vaccine for the prevention of active non-HIV-associated pulmonary tuberculosis. The study is di…
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 08, 2026 00:00 UTC
-
Can whole blood beat component transfusions in trauma?
Disease control Recruiting nowThe goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who re…
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Engineered immune cells take on tough lymphomas
Disease control Recruiting nowDALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymp…
Results expected Dec 2026 (estimated)
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Aiming to cure esophageal cancer without the knife
⭐️ CURE ⭐️ OngoingThe present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial investigating whether a definite organ preservation therapy consisting of the combination of durvalumab with chemoradiation is an efficient and safe treatment o…
Results expected Jan 2027 (estimated)
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: ⭐️ CURE ⭐️
Last updated Aug 09, 2026 00:00 UTC
-
New mRNA vaccine aims to stop the stomach flu
⭐️ VACCINE ⭐️ OngoingThe primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Results expected Feb 2027 (estimated)
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:33 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New drug aims to outdo chemo for lung cancer patients Who've run out of options
Disease control OngoingThis trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-sensitive mutations after EGFR-TKI failure.
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
Sichuan Baili Pharmaceutical Co., Ltd. · 688506 SSEReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Gene-Editing shot could slash cholesterol for good
Disease control Recruiting nowVT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-1…
Results expected Aug 2026 (estimated)
Phase: PHASE1 • Sponsor: Verve Therapeutics, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
Eli Lilly and Company · LLY NYSE Trade on eToro (ad)Reward if it works HighAn incremental result rather than a breakthrough.
Risk to the company HighA small company — one failure carries real weight.
-
Gene therapy shot could end monthly eye injections for wet AMD
Disease control OngoingThis interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being developed as a potential one-time gene therapy treatment for neovascular (wet) age-related macular degeneration (wet AMD or nAMD). …
Results expected Aug 2026 (estimated)
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
AbbVie · ABBV NYSE Trade on eToro (ad)Reward if it works ModerateAn incremental result rather than a breakthrough.
Risk to the company Very lowA large company running many trials — it absorbs a failure here.
-
New monthly shot could stop COVID-19 before it starts
Prevention OngoingThe main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is …
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Invivyd, Inc. • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
InVivyd · IVVD NASDAQ Trade on eToro (ad) -
New drug combo aims to outperform standard immunotherapy in stomach cancer
Disease control OngoingThis randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimbereli…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
Arcus Biosciences, Inc. · RCUS NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Could Self-Sampling revolutionize cervical cancer screening?
Diagnosis Recruiting nowTo evaluate whether individuals drawn from the intended use population can successfully interpret and follow the IFU for the Mia by XytoTest self-collection device and perform a vaginal sample collection yielding sufficient cellular material for primary hrHPV screening. To asses…
Results expected Aug 2026 (estimated)
Phase: NA • Sponsor: Mel Mont Medical • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
New hope for hepatitis delta: phase 3 trial of brelovitug launches
Disease control OngoingThis is a Phase 3, global, randomized, open-label, multicenter trial designed to evaluate the safety and efficacy of chronic treatment with brelovitug (BJT-778) for chronic hepatitis delta virus (HDV) infection. The objective of this study is to test the safety and effectiveness …
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New heart failure drug candidate targets patients with no other options
Disease control Recruiting nowFinerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Colorado Prevention Center • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New COVID-19 vaccine candidate tested alone or as a booster with mRNA shots
⭐️ VACCINE ⭐️ Recruiting nowThe main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in th…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Invivyd, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
InVivyd · IVVD NASDAQ Trade on eToro (ad) -
New antibody drug aims to tame ulcerative colitis in major trial
Disease control OngoingThe purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achiev…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
Merck & Co., Inc. · MRK NYSE Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
CRISPR therapy shows promise in early trial for fatal muscle disease
Disease control OngoingDuchenne muscular dystrophin (DMD) is an X-linked, fatal muscle-wasting disease caused by mutations in the DMD gene encoding the dystrophin proteins, with symptom onset before age of 6 years in boys. These mutations abolish dystrophin production in the muscle, leading to dystroph…
Results expected Aug 2026 (estimated)
Phase: EARLY_PHASE1 • Sponsor: HuidaGene Therapeutics Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Monthly shot could free kids with hemophilia from frequent infusions
Disease control OngoingPrimary Objective: \- To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to \<12 years of age) with severe hemophilia A or B Secondary Objectives: * To characterize the safety and tolerability * To determine fitusiran plasm…
Results expected Aug 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
Sanofi S.A. · SNY NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Can a short immunotherapy course shrink early breast tumors before surgery?
Disease control OngoingThis study aims to evaluate the efficacy and safety of preoperative Durvalumab in patients with early small (cT1N0) triple negative breast cancer tumors. This study will recruit patients with early HR-negative breast cancer all invasive types (ER \< 10%, PR \< 10%, HER2 negative)…
Results expected Aug 2026 (estimated)
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug aimed at tough breast cancer enters final testing phase
Disease control OngoingThis is a Phase III, randomized, open-label, 2-arm, multicentre, international study assessing the efficacy and safety of FDA018-ADC compared with Investigator's Choice Chemotherapy(ICC) in participants with locally recurrent inoperable or metastatic Triple-negative Breast Cancer…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · 1349 HKEXReward if it works HighA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Can a brain pacemaker tame Treatment-Resistant depression?
Disease control Recruiting nowThe goal of the study is to address the unmet need of TRD patients by identifying brain networks critical for treating depression and to use next generation precision DBS with steering capability to engage these targeted networks. The study's goal will be achieved through 3 speci…
Results expected Aug 2026 (estimated)
Phase: NA • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug duo aims to stall advanced breast cancer
Disease control OngoingThe study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Freezing tumors may boost immunotherapy in advanced lung cancer: new trial
Disease control Recruiting nowThis study aims to compare the one-year survival benefit of the association of cryoablation-pembrolizumab-pemetrexed-carboplatin versus pembrolizumab-pemetrexed-carboplatin in metastatic lung adenocarcinoma patients. This is a multicenter, prospective, open-labeled, 2-arm compar…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Scientists hunt for hidden genes behind sudden infant death
Knowledge-focused Recruiting nowThis is a multicenter genetic study aimed at identifying new genes/variants associated with sudden infant death syndrome (SIDS) based on whole-genome sequencing of family trios
Results expected Aug 2026 (estimated)
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Pap test DNA may spot ovarian cancer years before symptoms
Diagnosis Recruiting nowOvarian cancer is the leading cause of death among gynecological malignancies. No screening test is available for this tumor. Serous Tubal Intraepithelial Carcinoma (STIC) is the precursor lesion of the high grade serous ovarian cancer (HGSOC). Preliminary data suggest that tumor…
Results expected Aug 2026 (estimated)
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
New hope for stomach cancer: targeted drug shows promise in Late-Stage trial
Disease control OngoingThis study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-cont…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
Daiichi Sankyo Company, Limited · DSNKY OTCReward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to a broker we have a commercial relationship with, and we may earn a commission if you open an account. This never affects which trials are listed or how they are ranked.